9 June 2026

* JOIN US FOR THE PRE-EVENT HAPPY HOUR ON 8 JUNE 2026 FROM 18.00 – 19.00 CET

7.00 – 8.00 CET

Registration and Networking Breakfast

8:00 – 8:10 CET

CHAIR'S WELCOME AND OPENING REMARKS

PRODUCT DEVELOPMENT

Jelena Malinina

Director, Innovation and Digital Health
COCIR

Design & Innovation

Ravi Chana

Director, Diagnostics
Association of British Healthtech Industries

QUALITY & REGULATORY

Samantha Atkinson

CEO
TOPRA

8.10 – 8.40 CET

KEYNOTE

Peter Schulam

Chief Scientific Officer
Johnson & Johnson

Surgical Innovation: Experiences and Observations

  • Integrating clinical evidence generation into MedTech R&D from concept through post-market deployment
  • Applying AI and advanced analytics to reduce variability, improve decision-making, and accelerate responsible innovation
  • Leveraging real-world data from connected devices to monitor performance, manage risk, and drive continuous improvement
  • Designing AI-enabled products that align software, workflow, and clinician trust to deliver measurable clinical value
  • Establishing governance models for AI/ML-enabled devices that balance rapid iteration with MDR and global regulatory expectations
8.40 – 9.10 CET

Plenary

Dennett Kourijr

SVP, Corporate Quality, Regulatory and Clinical
Edwards Lifesciences

Inspection Readiness in Today’s High-Stakes Regulatory Landscape: Strategies for Resilience and Trust

  • Evolving inspection paradigms, from planned visits to dynamic, risk-based regulatory oversight, and what that means for global medtech leaders
  • Embedding inspection readiness into everyday operations, not just audit season, building systems that continuously demonstrate compliance
  • Coordinating quality, regulatory, and clinical functions to present consistent, defensible evidence across the product lifecycle
  • Leveraging data analytics and internal audit insights to anticipate inspection focus areas and prevent compliance gaps
  • Case examples from Edwards Lifesciences’ global quality and audit program demonstrating readiness practices that scale across geographies and regulatory regimes
9.10 – 9.40 CET

Plenary

Carsten Hurasky

SVP and Chief Marketing Officer
QNX

Build to Last, Design to Evolve: Foundational software design as a strategic enabler

  • Accelerate regulatory readiness by leveraging safety certifiable software frameworks that shorten development timelines, reduce risk, and streamline submission pathways.
  • Enable continuous innovation through a modular, platform-based architecture that simplifies post market surveillance and frees engineering teams to focus on differentiated clinical and commercial value.
  • Establish a secure, scalable, future proof technology foundation that ensures backward compatibility while supporting long-term product evolution and portfolio expansion.
  • Position your organization for the next wave of transformation, including seamless integration of emerging technologies such as Physical AI and intelligent edge capabilities.
9.45 – 11.25 CET

Refreshments, Networking, and Pre-Arranged 1-2-1 Meetings

11.30 – 12.00 CET

Streams

Product Development

Kathleen Van Vlierberghe

VP, Peripheral Interventions, EMEA
Boston Scientific

Strengthening Product Development Through Strategic Validation

  • Defining validation objectives early to align technical requirements with user needs and compliance goals
  • Integrating design validation with usability studies and risk management activities
  • Ensuring process validation readiness for scalable and repeatable manufacturing outcomes
  • Validating software elements and digital components in both embedded systems and connected products
  • Meeting EU MDR expectations for validation documentation, traceability, and evidence

Design & Innovation

Ola Hammarlund

Head, Digital Platforms
Getinge

ACCELERATING DIGITAL TRANSFORMATION IN MEDTECH THROUGH AI AND PLATFORM INNOVATION

  • Leveraging AI-driven solutions to support clinicians with real-time insights and decision-making tools
  • Integrating digital platforms to enhance device usability, serviceability, and overall efficiency
  • Addressing compliance, governance, and security challenges in deploying digital health technologies
  • Building cross-functional collaboration to secure executive buy-in and drive scalable innovation
  • Enabling patient safety and improved clinical outcomes through seamless human-technology interaction

Quality & Regulatory

Anders Rosengren

Chief Research and Development Officer
Sonova

Data-Driven Innovation And Prototyping: Key To Advancing R&D In Hearing Systems

  • Real-world evidence and user feedback from platforms like myPhonak to guide early-stage design and address customer/consumer needs
  • Integration of clinical and market data to validate concepts and prioritize features
  • Use of predictive analytics and simulation to forecast device performance and optimize patient outcomes
  • Cross-functional collaboration using shared data platforms to accelerate innovation
12.05 – 12.35 CET

Workshops

Room 1

Rupam Chaudhury

Chief Segment Office - MedTech
L&T Technology Services

Case in Point: How Digital & AI Gave a Global MedTech OEM a 6–9 Month Head Start and a Stronger Moat

  • How AI and digital engineering compressed product development cycles by 6–9 months
  • The engineering-first approach to embedding intelligence across the product lifecycle
  • Real-world ROI metrics and competitive differentiation achieved through digital transformation
  • A replicable framework for MedTech OEMs looking to accelerate concept-to-compliance timelines

Room 2

Dr. Günther Heling

Executive Consultant
Vector Informatik GmbH

Software Defined Systems – what Med and Auto can learn from each other

  • Lessons learned from history
  • Characteristics of a Software Defined System
  • Agile development methods suitable for safe and secure software
  • Software Ecosystems speeding up development of Medical Devices to reduce go- to-market time

Room 3

Andreas Beust, Ph.D.

Chief Executive Officer
GCP-Service International

Clinical Evidence for AI-based medical devices

  • Discussion of approaches to release retrained AI algorithms
  • Case study for notified body pre-approval to retrain AI algorithms
  • Overview of accompanying clinical evidence requirements
  • Impact of AI Act implementation
12.40 – 13.40 CET

Lunch & Learn Roundtable Discussions and Open Seating Lunch

Benefit from additional learning by joining a moderated roundtable discussion on pressing issues in the industry. Registration is required, and attendance for moderated roundtables on Day 1 is limited to attendees and speakers.
Choose from:

Rupam Chaudhury

Chief Segment Office - MedTech
L&T Technology Services

AI-Powered QARA: Moving Beyond Reactive Compliance to Predictive Quality

Kim Kaplan

Manager, Principal Product, MDDAP, LLC
The Voluntary Improvement Program

Collaborative Solutions for Overcoming Industry Barriers

Carsten Hurasky

SVP and Chief Marketing Officer
QNX

Innovation, not Fixation: Leveraging Foundational Software for Lifecycle Efficiency

Speaker TBA


Veeva MedTech

Cloud-Driven Transformation: Unifying Data, Quality, and Compliance in MedTech

Speaker TBA


Ketryx

From Bottleneck to Breakthrough: Making Compliance a Competitive Advantage in MedTech Innovation

Atul Mahajan

VP, Engineering Services
IZiel Healthcare

AI Transformation in MedTech: Lessons in Scaling and Adoption

13.45 – 14.15 CET

Streams

Product Development

Richard Willmann, Ph.D.

VP, R&D, Image-Guided Therapy Systems
Philips

Accelerating Innovation: Strategies for Next Generation Product Development in the age of AI

  • Embedding emerging technologies early to shape product roadmaps and deliver new clinical capabilities
  • Co designing with clinicians to integrate workflow insights and optimize usability from the start
  • Leveraging rapid prototyping and virtual simulation to shorten development cycles and reduce risk
  • Designing for interoperability, scalability, and manufacturability to ensure seamless integration and reliable production
  • Using real world data and feedback to drive continuous improvement and next generation innovation

Design & Innovation

Thomas Haeni

VP, Research and Development, Risk Prevention
Paul Hartmann AG

Designing for Sustainability in Single Use Medical Devices - Balancing Infection Prevention and Product Innovation

  • Understanding how sustainability targets from customers and legal obligations affect infection prevention requirements and product design
  • Addressing the challenge of aligning regulatory obligations with practical design, performance expectations and sustainability requirements
  • Case insights: successfully integrating regulatory, sustainability & product performance considerations early in R&D pipelines
  • Discussing frameworks for cross-functional collaboration between engineering, marketing, sustainability and regulatory teams
  • Identifying opportunities for innovation in meeting both sustainability and safety and compliance standards in medical device

Quality & Regulatory

Michael Schiffner

VP, Quality, EMEA and CWE
Siemens Healthineers

Accelerating Quality Excellence Through Regulatory Innovation

  • Leveraging digital quality management systems to optimize CAPA and change control processes
  • Embedding regulatory intelligence to anticipate global harmonization and emerging compliance trends
  • Scaling virtual audits and remote inspections via secure data-sharing platforms
  • Driving continuous improvement by analyzing post-market data and regulatory feedback loops
  • Cultivating a quality-first culture across operations to support rapid product introduction
14.20 – 14.50 CET

Workshops

Room 1

Kim Kaplan

Manager, Principal Product, MDDAP, LLC
The Voluntary Improvement Program

Improve Business Performance and Risk Maturity in Alignment with the FDA's QMSR

  • Learn how VIP evaluates the way risks are documented, tracked, and analyzed for bi-directional traceability and proportional mitigation or contingency strategies
  • See Final Guidance “Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program”
  • Leveraging US FDA opportunities for expedited PMA and Site Change submissions, and more
  • Boosting capacity and quality using an approach that meets your business needs
  • Provide faster market access and increase sales while meeting product quality and safety standards

Room 2

Priya Bhutani

Founder and CEO
RegDesk

What High-Growth Companies Do Differently in Regulatory: From Compliance Function to Strategic Growth Engine

  • How high-growth companies shift regulatory from a compliance function to a strategic driver of business growth
  • Key differences between traditional regulatory models and scalable, strategy-led operating models
  • Using a regulatory maturity framework to assess current capabilities and identify transformation opportunities
  • The role of data-centric regulatory management in improving efficiency, visibility, and decision-making
  • How modular submission design supports scalability and faster global market access
  • Leveraging integrated regulatory intelligence to navigate global divergence and inform strategic planning

Room 3

Bastian Krapinger-Rüther

CEO
Flinn.ai

From Literature to Intelligence: The Evidence Gap MedTech Hasn’t Solved

  • Most MedTech organisations treat clinical literature as a project input rather than a shared asset
  • Evidence gets rebuilt from scratch each CER cycle, stays locked in one person’s spreadsheet, and never reaches the R&D or Quality teams who need it most.
  • Structured evidence infrastructure turns literature into a queryable, reusable knowledge base that serves Regulatory Affairs, Clinical Affairs, R&D, and Quality from a single source of truth.
  • To break the silo, you need to prove benefits and return on investment every step of the way: efficiency & quality gains in clinical teams are the start
14.55 - 16.15 CET

Refreshments, Networking, and Pre-Arranged 1-2-1 Meetings

16.20 – 17.05 CET

Panel Discussion

  • Thierry Glauser, Ph.D.

    VP, Research and Development
    Teleflex

  • Sophie Sheedy

    VP, Process Engineering
    Cochlear

  • Matthieu Menut

    VP, Product Divisions, EMEA
    Medline

  • Juan-Carlos Celi, Ph.D

    VP and Head, Oncology Software Solutions Region Europe
    Elekta

  • Karsten Klose, Ph.D.

    SVP, Global Digital Unit
    Olympus Corporation

Shaping the Future of Medical Device Innovation Through Innovative Product Development

  • Exploring how emerging technologies are reshaping device innovation
  • Maintaining agility in product development amid evolving AI regulations
  • Using real-world evidence and data analytics to enhance design decisions and iteration
  • Ensuring scalability across diverse care settings and patient populations
  • Identifying disruptive forces likely to redefine medtech innovation over the next decade
17.05 – 17.35 CET

Plenary

  • Annemien Pullen

    VP, MedTech Strategy, EU
    Veeva MedTech

The Unified Medtech Enterprise: Bridging Quality, Regulatory, Commercial and Clinical for the Next Era of Innovation

  • How to quantify the impact of departmental silos on regulatory risk and commercial launch
  • Strategies to optimize data flows ensuring clinical milestones trigger real-time regulatory and quality updates
  • Best practices for integrating data for predictive analytics in medtech R&D
17.35 – 18.20 CET

Panel Discussion

  • Dennett Kouri

    SVP, Corporate Quality and Regulatory
    Edwards Lifesciences

  • Scott Kaplan

    SVP, Quality, Regulatory Affairs, and Patient Safety
    Baxter

  • Nickerson Hill

    VP, Global Clinical Research and Regulatory Affairs
    LivaNova

  • Susana de Azevedo Wäsch, Ph.D.

    VP, Quality Management and Regulatory Affairs and Medical Affairs
    Ypsomed

  • Michael Schiffner

    VP, Quality, EMEA and CWE
    Siemens Healthineers

Understanding how evolving MDR and global regulations are reshaping quality expectations

  • Implementing modern QMS frameworks that support agility, transparency, and innovation
  • Striking the right balance between accelerating innovation and maintaining rigorous safety standards
  • Anticipating and mitigating quality risks through proactive, data-driven decision-making
  • Leveraging cross-functional collaboration to build a culture of quality across the product lifecycle
  • Defining the next phase of regulatory and quality excellence through shared lessons and emerging best practices
18.20 - 18.25 CET

Chair's closing remarks

PRODUCT DEVELOPMENT

Jelena Malinina

Director, Innovation and Digital Health
COCIR

Design & Innovation

Ravi Chana

Director, Diagnostics
Association of British Healthtech Industries

QUALITY & REGULATORY

Samantha Atkinson

CEO
TOPRA

18.25 - 19.25 CET

NETWORKING DRINKS RECEPTION

Unlock Exclusive Summit Details

Exclusive summit content is reserved for qualified participants—request access today or enter your password.